Actively Recruiting
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Led by Hyundai Pharm · Updated on 2024-08-29
56
Participants Needed
1
Research Sites
23 weeks
Total Duration
On this page
Sponsors
H
Hyundai Pharm
Lead Sponsor
K
Kyungpook National University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
CONDITIONS
Official Title
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Age 19 years and older, healthy volunteer
- Body mass index (BMI) between 18.5 and 29.9 kg/m2
You will not qualify if you...
- Presence of incompletely cured pre-existing diseases affecting drug absorption, distribution, metabolism, elimination, or effects
- Clinically relevant abnormal findings in blood pressure, electrocardiogram (ECG), physical and gynecological examination, or laboratory tests
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kyungpook national university hospital
Daegu, Gyeongsangbuk-do, South Korea
Actively Recruiting
Research Team
Y
Young-Ran Yoon, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here